Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice

Table 2 Metabolic and anthropometric parameters of lean (control) and obese (high-fat diet) mice treated with pentoxifylline

	Control		HFD
	NT	PTX	NT	PTX
Final BW (g)	34.2 ± 1.0	37.0 ± 2.0	51.6 ± 1.5a	52.0 ± 2.7
Liver (g)	1.7 ± 0.2	1.7 ± 0.0	2.6 ± 0.2a	1.7 ± 0.0c
Liver (% of BW)	4.1 ± 0.0	4.6 ± 0.1c	4.8 ± 0.2a	3.3 ± 0.0c
Visceral adipose tissue (g)	0.8 ± 0.1	0.9 ± 0.2	1.8 ± 0.2a	2.7 ± 0.1c
Visceral adipose tissue (% of BW)	2.2 ± 0.2	2.4 ± 0.4	3.4 ± 0.3a	5.4 ± 0.4c
Blood glucose (mg/dL)	120.6 ± 6.8	131.0 ± 3.0	178.6 ± 10a	141.0 ± 16
kITT	4.0 ± 0.6	3.6 ± 0.3	2.1 ± 0.1a	1.6 ± 0.3
Insulin (ng/mL)	0.4 ± 0.1	0.4 ± 0.2	4.4 ± 2.0a	4.5 ± 1.2
AST (U/L)	19.4 ± 4.6	9.4 ± 2.3a	23.2 ± 6.9	12.1 ± 1.6c
ALT (U/L)	3.12 ± 0.9	9.0 ± 2.0a	2.25 ± 0.9	4.2 ± 1.5

^aP < 0.05 vs control NT group;

^cP < 0.05 vs paired NT group. HFD: High-fat diet; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; PTX: Pentoxifylline; BW: Body weight; NT: Non-treated; kITT: Rate constant for glucose disappearance during an insulin tolerance test.